Amicus receives rare pediatric disease designation for EB candidate SD-101

Amicus Therapeutics Inc. (NASDAQ:FOLD) said FDA granted rare pediatric disease designation to SD-101 to treat epidermolysis bullosa (EB). Amicus expects data in 3Q17 from the Phase III ESSENCE trial of SD-101 in patients with simplex, recessive dystrophic or junctional non-Herlitz EB...